Rónai A Z, Magyar A, Orosz G, Borsodi A, Benyhe S, Tóth G, Makó E, Kátay E, Babka E, Medzihradszky K
Research Group of Peptide Chemistry, Hungarian Academy of Sciences, L. Eötvös University, Budapest, Hungary.
Arch Int Pharmacodyn Ther. 1995 Nov-Dec;330(3):361-9.
BOC-Tyr-Pro-Gly-Phe-Leu-Thr(OtBu) is a potent, highly delta-opioid receptor-selective competitive antagonist, the Ke values in the mouse vas deferens in vitro assay against [D-Ala2, D-Leu5]-enkephalin [D-Pen2, D-Pen5]enkephalin and deltorphin-II being 39.5, 38.7 and 27.3 nM, respectively, whereas those against [D-Ala2, MePhe4-Gly5-ol]enkephalin (DAMGO) and ethylketocyclazocine in the guinea-pig ileum are 368,000 and > 200,000 nM, giving a higher than 9000-fold delta- vs mu- and a higher than 5000-fold delta- vs kappa-selectivity ratio. The Ki values against various labeled delta-ligands in the rat brain receptor binding assay were in the 300-1000 nM range, whereas the Ki against [3H]-DAMGO was higher than 30,000 nM. The striking discrepancies between bioassay and receptor binding data show another aspect of already recognized differences of mouse vas deferens and rat brain delta-receptors. With the aim of producing a delta-selective affinity ligand, we synthesized the BOC-Mel1 derivative; however, there was a 175-fold loss of delta-receptor affinity in the bioassay and no indication of an irreversible interaction, but a delta-agonist effect appeared in spite of nonprotonated nitrogen. The corresponding BOC-Phe1 derivative had a 10 times higher affinity and, apparently, no agonist activity.
BOC-Tyr-Pro-Gly-Phe-Leu-Thr(OtBu)是一种强效、高度δ-阿片受体选择性竞争性拮抗剂,在小鼠输精管体外试验中,其针对[D-Ala2, D-Leu5]-脑啡肽、[D-Pen2, D-Pen5]脑啡肽和强啡肽-II的Ke值分别为39.5、38.7和27.3 nM,而在豚鼠回肠中针对[D-Ala2, MePhe4-Gly5-ol]脑啡肽(DAMGO)和乙基酮环唑新的Ke值分别为368,000和>200,000 nM,δ-与μ-的选择性比高于9000倍,δ-与κ-的选择性比高于5000倍。在大鼠脑受体结合试验中,其针对各种标记的δ-配体的Ki值在300 - 1000 nM范围内,而针对[3H]-DAMGO的Ki值高于30,000 nM。生物测定和受体结合数据之间的显著差异显示了已认识到的小鼠输精管和大鼠脑δ-受体差异的另一个方面。为了制备一种δ-选择性亲和配体,我们合成了BOC-Mel1衍生物;然而,在生物测定中其δ-受体亲和力损失了175倍,且没有不可逆相互作用的迹象,尽管氮未质子化,但仍出现了δ-激动剂效应。相应的BOC-Phe1衍生物的亲和力高10倍,且显然没有激动剂活性。